Arcutis Biotherapeutics (ARQT) Stock
$27.39
+4.52% Close Nov 10
ARQT stock is in a sideways trend, in Stage 2 (advancing), and does not meet the Minervini Trend Template
Open interactive chartARQT stock price and performance
ARQT stock trades on NASDAQ in the Healthcare sector and the Biotechnology industry. The live price table and chart beside this text show the price, returns and moving averages, and they update each session. Readers can follow those tables alongside the trend and level notes on this page.
- Last close
- $27.39
- Day range
- $25.82 to $27.62
- 52-week range
- $19.30 to $34.80
- From 52-week high
- −21.3%
- Average volume (50 days)
- 2.9M
- 1 week
- −14.4%
- 1 month
- +4.4%
- 3 months
- +4.2%
- Year to date
- −5.7%
- 1 year
- +13.0%
- 3 years
- +1,022.3%
- 5 years
- +19.3%
Is ARQT stock in an uptrend?
Not yet. ARQT stock is not in an uptrend by our rules: it does not meet the Minervini Trend Template criteria and neither Daily Pivot Breakout momentum filter is active. Price is above its 200-day moving average.
ARQT stock is in a sideways trend by the trend rules on this page, and it does not meet the Minervini Trend Template. The Template checks whether the 50-day, 150-day and 200-day moving averages are stacked in order and whether the stock holds its position in the yearly range. The Daily Pivot Breakout momentum filters measure the 100-day rate of change and the 100-day EMA slope, each compared with a minimum. Stage 2 (advancing) is a price above a rising 30-week moving average, and the Mansfield relative strength shows how the stock performs against the broader market.
- Daily Pivot momentum filters
- 0 of 2 active
- 100-day ROC
- +4.5% filter at 40%: off
- 100-day EMA slope
- +15.3% filter at 25%: off
- Trend state
- Sideways
- Minervini Trend Template
- Not met on the latest scan
- 50-day average
- Above
- 150-day average
- Above
- 200-day average
- Above
- 200-day slope (1 month)
- +0.98%
- ATR (14) % of price
- 6.57%
Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.
Is ARQT stock in a Stage 2 uptrend?
Yes, ARQT stock is in a Stage 2 uptrend by our Weinstein stage analysis: its price is above a rising 30-week moving average and it is outperforming SPY.
- Weinstein stage
- Stage 2 (advancing)
- 30-week SMA
- $25.46
- 30-week slope (4 weeks)
- +3.05%
- Mansfield RS vs SPY
- 1.61
- Weeks in Stage 2
- 1
Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.
ARQT support and resistance levels
ARQT stock's support and resistance levels appear as pivot high, pivot low and moving-average lines in the levels table. The table handles the spacing between each line and the live quote, so the figures stay on the table.
| Level | Price | From close |
|---|---|---|
| Daily Pivot resistance (pivot high) | $33.30 | +21.6% |
| 21-day EMA | $29.18 | +6.5% |
| 9-day EMA | $28.80 | +5.2% |
| 50-day SMA | $27.28 | −0.4% |
| 150-day SMA | $25.55 | −6.7% |
| 30-week SMA | $25.46 | −7.1% |
| 200-day SMA | $25.34 | −7.5% |
| Latest Daily Pivot low | $23.37 | −14.7% |
Levels above the close act as resistance, levels below as support. Last close $27.39.
ARQT breakout and scanner signals
ARQT stock is tracked by the VCP, RSI Divergence, Weinstein Stage Analysis, Daily Pivot Breakout, Minervini Trend Template, Episodic Pivot, Ichimoku TK cross, 9/21 EMA cross, Golden / Death Cross and RS Rating scanners. The signal table lists the signal dates and directions for each of these scanners. Readers can filter the table by scanner to follow one setup at a time.
| Scanner | Last signal (free view, 5 sessions late) | Past year |
|---|---|---|
| VCP | Jan 5, 2026 | 1 |
| RSI Divergence | Sep 29, 2026 (bearish) | 3 |
| Weinstein Stage Analysis | Nov 3, 2026A more recent signal (last 5 sessions) is in the journal. | 95 |
| Daily Pivot Breakout | Mar 31, 2026 | 4 |
| Minervini Trend Template | Apr 14, 2026A more recent signal (last 5 sessions) is in the journal. | 45 |
| Episodic Pivot | Oct 28, 2025 | 0 |
| Ichimoku TK cross | Oct 15, 2026 | 12 |
| 9/21 EMA cross | Oct 12, 2026A more recent signal (last 5 sessions) is in the journal. | 12 |
| Golden / Death Cross | Jul 31, 2026 | 2 |
| RS Rating | Dec 8, 2025 | 15 |
ARQT seasonality by month
The monthly pattern on this page shows ARQT stock has historically been strongest in February and weakest in October. These are past tendencies drawn from historical months, and they describe the record rather than a forecast.
- Jan+7.7%33% up
- Feb+21.1%86% up
- Mar−4.1%43% up
- Apr+3.4%43% up
- May−10.1%43% up
- Jun+9.1%86% up
- Jul+2.4%71% up
- Aug−3.2%43% up
- Sep−2.9%57% up
- Oct−10.1%29% up
- Nov+14.6%50% up
- Dec+15.3%67% up
Average monthly return over 6+ years of stored daily closes, and the share of years each month closed higher.
ARQT earnings history
ARQT stock last reported quarterly results on Nov 4, 2026, and the results came in below the estimate. The earnings result is written in words on this page. The earnings date and result sit alongside the trend and signal sections for context.
| Reported | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 4, 2026 | $0.17 | $0.06 | −64.7% |
| Aug 5, 2026 | $0.05 | $0.11 | +120.0% |
| May 6, 2026 | $-0.06 | $-0.09 | −50.0% |
| Feb 25, 2026 | $0.09 | $0.13 | +44.4% |
| Nov 4, 2025 | $3.16 | $3.01 | −4.8% |
ARQT bull and bear case
Bullish factors for ARQT stock include its Stage 2 (advancing) classification and the Daily Pivot Breakout momentum filters, which measure rate of change and EMA slope. Bearish factors include the sideways trend state, the failure to meet the Minervini Trend Template and the last reported quarter result coming in below the estimate.
What looks strong
- Stage 2 uptrend by our Weinstein stage analysis scanner.
- The 50, 150 and 200-day averages are stacked in uptrend order.
- Price is above a rising 200-day moving average.
What looks weak
- Neither Daily Pivot momentum filter is active (100-day ROC 4.5%, 100-day EMA slope 15.3%; the filters need 40% and 25%).
- Does not meet the Minervini Trend Template on the latest scan.
- Short interest is 17.33% of shares outstanding.
Drawn only from the data on this page. Not a recommendation.
ARQT news and SEC filings, last 30 days
ARQT stock has a filings table that lists the company's SEC filings. Each row shows the filing as the live table records it. Readers can use the table to find the source documents for the company's reports.
- 8-KQuarterly or annual results; Exhibits
- 10-QQuarterly report (10-Q)
- 4FORM 4
- 4FORM 4
- 4FORM 4
- 4FORM 4
- 8-KExecutive or director change; Reg FD disclosure; Exhibits
- 4FORM 4
Source: SEC EDGAR.
ARQT insider trading and risks
The insider table on this page lists insider trades in ARQT stock. Each row shows the reported transaction and its direction. Readers can scan the rows to see whether insiders have been buying or selling the shares.
- Buys, last 90 days
- 0 ($0)
- Sales, last 90 days
- 5 ($1.7M)
- Buys, last 12 months
- 0 ($0)
- Sales, last 12 months
- 5 ($1.7M)
| Date | Insider | Trade | Value |
|---|---|---|---|
| Nov 4 | Matsuda MasaruEVP, Chief Legal Officer | Sale 40,000 shares | $1.4M |
| Nov 2 | Watanabe ToddDirector, See Remarks | Sale 4,377 shares | $139,466 |
| Oct 15 | Welgus Howard G.Director | Sale 4,728 shares | $127,325 |
| Nov 2 | Matsuda MasaruEVP, Chief Legal Officer | Sale 1,219 shares | $38,841 |
| Nov 2 | Burnett PatrickEVP, Chief Medical Officer | Sale 943 shares | $30,047 |
Risk flags from the data
- Short interest is 17.33% of shares outstanding.
Insider trades: SEC Form 4 open-market purchases and sales.
ARQT valuation and fundamentals
ARQT stock has valuation data on this page, and the valuation table lists the measures built from the company's financial statements. Readers can use the table to see how the shares are valued against those measures.
- Market cap
- $3.23B
- Enterprise value
- $3.10B
- P/E (trailing)
- 116.1
- P/E (forward)
- 19.1
- PEG
- -0.63
- Price to sales
- 6.35
- Price to book
- 13.20
- EV to EBITDA
- 82.7
- Gross margin
- +91.6%
- Operating margin
- +6.6%
- Profit margin
- +5.9%
- Return on equity
- +14.9%
- Revenue (TTM)
- $508.7M
- Revenue growth (quarter, y/y)
- +45.1%
- Cash
- $259.5M
- Debt
- $123.8M
- Beta
- 1.63
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $376.1M | −$16.1M | −$5.6M |
| 2024 | $196.5M | −$140.0M | −$136.2M |
| 2023 | $59.6M | −$262.1M | −$238.3M |
| 2022 | $3.7M | −$311.5M | −$260.5M |
ARQT dividends and splits
ARQT stock does not pay a dividend. The dividend table lists dates and amounts for any distributions recorded for the company, so the table reflects only what has been paid.
- Dividend yield
- 0.00%
- Payout ratio
- 0.0%
Who owns ARQT?
- Shares outstanding
- 125.6M
- Float
- 94.4M
- Held by insiders
- +1.8%
- Held by institutions
- +108.6%
- Short interest (% of shares)
- +17.3%
- Days to cover
- 6.1
What does Arcutis Biotherapeutics, Inc. do?
ARQT stock belongs to Arcutis Biotherapeutics, Inc., a commercial-stage medical dermatology company. Its portfolio centers on ZORYVE, a branded topical treatment platform used in immune-mediated skin conditions. The company also advances a pipeline of dermatology candidates, and it is based in Westlake Village, California.
- CEO
- Mr. Todd Franklin Watanabe M.A.
- Employees
- 354
- Headquarters
- Westlake Village, CA, United States
- Website
- arcutis.com
ARQT stock FAQ
Is ARQT stock in an uptrend?
Not yet. ARQT stock is not in an uptrend by our rules: it does not meet the Minervini Trend Template criteria and neither Daily Pivot Breakout momentum filter is active. Price is above its 200-day moving average.
Is ARQT stock in a Stage 2 uptrend?
Yes, ARQT stock is in a Stage 2 uptrend by our Weinstein stage analysis: its price is above a rising 30-week moving average and it is outperforming SPY.
Does ARQT stock meet the Minervini Trend Template?
ARQT stock does not meet the Minervini Trend Template on this page. The Template checks whether the 50-day, 150-day and 200-day moving averages are stacked in order and whether the stock holds its position in the yearly range.
What are ARQT stock's support and resistance levels?
ARQT stock's levels appear as pivot high, pivot low and moving-average lines in the levels table. The table shows how each line relates to the live quote, so readers can compare them directly.
When did ARQT last report earnings?
ARQT stock last reported earnings on Nov 4, 2026, and the results came in below the estimate.
Are insiders buying or selling ARQT stock?
The insider table on this page lists each reported insider trade in ARQT stock with its direction. Scan the rows to see the buying and selling recorded for the shares.
What is ARQT stock's best and worst month historically?
February has been ARQT stock's strongest month and October its weakest, based on the monthly pattern shown on this page.
Does ARQT stock pay a dividend?
ARQT stock does not pay a dividend. The dividend table lists dates and amounts for any distributions recorded for the company.
What does ARQT do?
ARQT stock belongs to Arcutis Biotherapeutics, a commercial-stage medical dermatology company focused on immune-mediated skin diseases. Its ZORYVE topical platform sits at the center of the portfolio.
What sector and industry is ARQT stock in?
ARQT stock is in the Healthcare sector and the Biotechnology industry, and it trades on NASDAQ.
